Elvir-Lazo Ofelia Loani, White Paul F, Yumul Roya, Cruz Eng Hillenn
Department of Anesthesiology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
The White Mountain Institute, The Sea Ranch, Sonoma, CA, 95497, USA.
F1000Res. 2020 Aug 13;9. doi: 10.12688/f1000research.21832.1. eCollection 2020.
Postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting (PDNV) remain common and distressing complications following surgery. The routine use of opioid analgesics for perioperative pain management is a major contributing factor to both PONV and PDNV after surgery. PONV and PDNV can delay discharge from the hospital or surgicenter, delay the return to normal activities of daily living after discharge home, and increase medical costs. The high incidence of PONV and PDNV has persisted despite the introduction of many new antiemetic drugs (and more aggressive use of antiemetic prophylaxis) over the last two decades as a result of growth in minimally invasive ambulatory surgery and the increased emphasis on earlier mobilization and discharge after both minor and major surgical procedures (e.g. enhanced recovery protocols). Pharmacologic management of PONV should be tailored to the patient's risk level using the validated PONV and PDNV risk-scoring systems to encourage cost-effective practices and minimize the potential for adverse side effects due to drug interactions in the perioperative period. A combination of prophylactic antiemetic drugs with different mechanisms of action should be administered to patients with moderate to high risk of developing PONV. In addition to utilizing prophylactic antiemetic drugs, the management of perioperative pain using opioid-sparing multimodal analgesic techniques is critically important for achieving an enhanced recovery after surgery. In conclusion, the utilization of strategies to reduce the baseline risk of PONV (e.g. adequate hydration and the use of nonpharmacologic antiemetic and opioid-sparing analgesic techniques) and implementing multimodal antiemetic and analgesic regimens will reduce the likelihood of patients developing PONV and PDNV after surgery.
术后恶心呕吐(PONV)和出院后恶心呕吐(PDNV)仍然是手术后常见且令人痛苦的并发症。围手术期常规使用阿片类镇痛药进行疼痛管理是术后PONV和PDNV的主要促成因素。PONV和PDNV会延迟从医院或手术中心出院,延迟出院回家后恢复正常日常生活活动,并增加医疗费用。尽管在过去二十年中引入了许多新型止吐药物(以及更积极地使用止吐预防措施),但由于微创门诊手术的增加以及对小型和大型手术(如强化康复方案)后更早活动和出院的重视增加,PONV和PDNV的高发生率仍然持续存在。PONV的药物管理应根据患者的风险水平,使用经过验证的PONV和PDNV风险评分系统进行调整,以鼓励具有成本效益的做法,并最大限度地减少围手术期药物相互作用导致的潜在副作用。对于发生PONV风险为中度至高度的患者,应给予具有不同作用机制的预防性止吐药物联合使用。除了使用预防性止吐药物外,采用阿片类药物节省的多模式镇痛技术管理围手术期疼痛对于实现术后更好的恢复至关重要。总之,采用降低PONV基线风险的策略(如充分补液以及使用非药物性止吐和阿片类药物节省的镇痛技术)并实施多模式止吐和镇痛方案将降低患者术后发生PONV和PDNV的可能性。